Vitreous Inflammatory Cytokines and Chemokines, Not Altered After Preoperative Adjunctive Conbercept Injection, but Associated With Early Postoperative Macular Edema in Patients With Proliferative Diabetic Retinopathy.
anti-VEGF
chemokines
cytokines
inflammation
macular edema
proliferative diabetic retinopathy
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
12
2021
accepted:
15
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
To investigate the influence of preoperative adjunctive anti-VEGF drug (Conbercept) on vitreous inflammatory cytokines and chemokines profiles and whether those cytokines were associated with early macular edema (ME) after surgery for patients with proliferative diabetic retinopathy (PDR). In this There was no difference between Pre-IV (13/30) and No-Pre-IV (7/29) concerning the ratio of patients with early ME ( We found the preoperative adjunctive Conbercept injection has limited influence on the levels of vitreous inflammatory cytokines and chemokines in PDR. The elevated levels of a series of cytokines might be associated with early inflammation after vitrectomy, which may lead to postoperative ME.
Identifiants
pubmed: 35309074
doi: 10.3389/fphys.2022.846003
pmc: PMC8928061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
846003Informations de copyright
Copyright © 2022 Sun, Zou, Zhang, Huang, Zhao, Qin, Xie, Mugisha, Liu and Hu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Ophthalmol. 2019 Oct;206:176-183
pubmed: 30959004
Am J Ophthalmol. 2021 Feb;222:328-339
pubmed: 32896498
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2597-2603
pubmed: 33772356
Mediators Inflamm. 2013;2013:943409
pubmed: 24307762
Cell Death Dis. 2021 Nov 8;12(11):1057
pubmed: 34750361
J Ocul Pharmacol Ther. 2020 Nov;36(9):697-702
pubmed: 32589498
Front Immunol. 2020 Nov 06;11:564077
pubmed: 33240260
Indian J Ophthalmol. 2021 Jun;69(6):1475-1481
pubmed: 34011723
Acta Ophthalmol. 2022 Feb;100(1):e53-e70
pubmed: 33945678
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2695-2705
pubmed: 33710470
Retina. 2018 Jun;38(6):1127-1133
pubmed: 28489694
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Prog Retin Eye Res. 2016 Mar;51:156-86
pubmed: 26297071
Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):187-197
pubmed: 30377797
J Ophthalmol. 2016;2016:2473234
pubmed: 27034822
Prog Retin Eye Res. 2019 Sep;72:100756
pubmed: 30951889
Acta Ophthalmol. 2014 May;92(3):e217-24
pubmed: 23889803
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5382-5390
pubmed: 30452591
Br J Ophthalmol. 2015 Jul;99(7):960-6
pubmed: 25631486
Am J Ophthalmol. 2017 Nov;183:1-10
pubmed: 28860046
Br J Ophthalmol. 2018 Oct;102(10):1351-1357
pubmed: 29343528
J Ophthalmol. 2021 Jul 13;2021:9947250
pubmed: 34336263
Sci Rep. 2018 Nov 8;8(1):16548
pubmed: 30410092
J Neuroinflammation. 2014 Jun 03;11:98
pubmed: 24889886
Ophthalmologica. 2017;238(4):186-195
pubmed: 28728160
Acta Ophthalmol. 2021 Aug 17;:
pubmed: 34403203
Acta Ophthalmol. 2021 Jul 14;:
pubmed: 34260829
Am J Ophthalmol. 2013 Jul;156(1):106-115.e2
pubmed: 23791371
Drug Des Devel Ther. 2019 Dec 24;13:4367-4374
pubmed: 31920286
Sci Rep. 2018 Jan 18;8(1):1098
pubmed: 29348424
Prog Retin Eye Res. 2021 Sep;84:100940
pubmed: 33429059
Ophthalmic Res. 2021;64(1):43-49
pubmed: 32454504
Retina. 2017 Apr;37(4):761-769
pubmed: 27471825
Exp Mol Med. 2016 Dec 16;48(12):e280
pubmed: 27980343
Curr Eye Res. 2020 Apr;45(4):509-520
pubmed: 31488015
Cytokine. 2012 Nov;60(2):535-9
pubmed: 22846147
JAMA Ophthalmol. 2018 Apr 1;136(4):382-388
pubmed: 29522144
Ophthalmology. 2017 Jun;124(6):757-767
pubmed: 28237428
Am J Ophthalmol. 2011 Oct;152(4):686-94
pubmed: 21782151
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1611-1619
pubmed: 31053944